Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
ALK tyrosine kinase inhibitor

Alecensa (alectinib)

An approved treatment for ALK-Positive Lung Cancer.

FDA Approved (2015)by Genentech, a member of the Roche Group
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2015

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Alectinib wherever you encounter it, plus the key facts at a glance.

Generic name
Alectinib
Brand name
Alecensa
Development code
RO5424802
Drug class
ALK tyrosine kinase inhibitor
Manufacturer
Genentech, a member of the Roche Group
How it's taken
Oral capsules, twice a day with food

Alecensa (alectinib) is a capsule taken twice a day with food for adults with ALK-positive non-small cell lung cancer found by an FDA-approved test[1].

  • The label covers 2 uses[1].
  • The first is metastatic disease, meaning cancer that has spread, where Alecensa is taken until the cancer grows or side effects become too hard to manage[1].
  • The second is adjuvant treatment after surgery has removed the tumor, for tumors 4cm or larger or cancer found in the lymph nodes.
  • In this use, Alecensa is taken for a total of 2 years unless the cancer comes back or side effects become too hard to manage[1].
  • The FDA first granted accelerated approval on December 11, 2015[2]. It approved Alecensa as a first treatment for metastatic disease on November 6, 2017[3].
  • The FDA then approved the after-surgery use on April 18, 2024[5].
  • In the ALINA trial after surgery, the main analysis counted people whose cancer came back, who had a new lung cancer or who died. This happened in 12% of the alectinib group and 39% of the chemotherapy group[1].
Follow Alecensa by email

We'll email you when Alecensa's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Alectinib fits

Alecensa (alectinib) is a twice-daily ALK inhibitor capsule approved for metastatic ALK-positive lung cancer. It is also approved for 2 years after surgery for early-stage ALK-positive lung cancer with tumors 4cm or larger or cancer in the lymph nodes[1].

  • Among the 7 FDA-approved ALK inhibitors, Alecensa is the only one whose label includes use after surgery. This is based on Trial Friend's reading of all 7 current labels on November 18, 2026[1][13][14][15][16][17][18].
  • Lorlatinib (Lorbrena), brigatinib (Alunbrig), crizotinib (Xalkori) and ceritinib (Zykadia) are also approved for metastatic ALK-positive lung cancer[13][14][15][16].
  • Ensartinib (Ensacove) is approved for people who have not yet taken an ALK inhibitor[17].
  • Nelkarmi (neladalkib) received accelerated approval in November 2026 for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. It covers people already treated for advanced or metastatic disease with either alectinib as their only ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy[18].
  • ALEX compared alectinib with crizotinib, and ALINA compared it with platinum chemotherapy after surgery[1].
  • The first-treatment trials in the brigatinib, lorlatinib and ensartinib labels also used crizotinib as the comparison[14][13][17].
  • None of these labels describes a trial comparing alectinib directly with brigatinib, lorlatinib or ensartinib in people starting treatment[1][14][13][17].
  • Outside the labels, the Phase 3 ALTA-3 trial compared brigatinib with alectinib in 248 people whose cancer had grown on crizotinib. It found no significant difference in the time before the cancer grew.
  • By independent review, the median was 19.3 months on brigatinib and 19.2 months on alectinib[10].
  • The Phase 3 ALKAZAR trial is sponsored by Nuvalent, is still recruiting and has no results yet. It is comparing neladalkib with alectinib in people with advanced ALK-positive lung cancer who have not had drug treatment for it[11].
  • Anyone curious about alectinib can ask their oncologist whether their surgery results and stage fit the after-surgery use.
  • If the cancer has spread, they can ask which ALK pill fits their health history.

How Alectinib works

In ALK-positive lung cancer, a piece of the ALK gene joins another gene inside the tumor, most often one called EML4. LUNGevity explains that the fused gene makes an abnormal ALK protein that keeps telling cancer cells to grow[12]. LUNGevity also notes that this change is acquired during life rather than inherited from a parent[12]. Alectinib is a kinase inhibitor, a pill that blocks the ALK protein's growth signal and the signals it passes on inside the cell[1].

The body turns alectinib into a breakdown product called M4 that works about as strongly as alectinib itself[1]. In laboratory tests, alectinib and M4 blocked several changed forms of ALK found in tumors that had grown on crizotinib[1]. Alectinib also lengthened survival in mice with ALK-driven tumors placed in the brain[1]. Besides ALK, alectinib blocks a related protein called RET[1].

Side effects and safety

What patients report

Alecensa has no boxed warning and no contraindications[1]. The label's 8 warnings start with liver injury, lung inflammation, kidney problems and a slow heart rate. They also include severe muscle pain with a rise in the muscle enzyme CPK, and a type of anemia in which red blood cells break apart. The other warnings are very high triglycerides that can lead to pancreatitis, and harm to an unborn baby[1].

Most common: The label combines results from 533 people in 4 trials. The most common side effects were liver test changes or liver injury (41%), constipation (39%), tiredness (36%) and muscle pain (31%). Swelling (29%), rash (23%) and cough (21%) were also common[1].

Liver: Liver side effects were severe in 8% of the 533 people, and in the after-surgery ALINA trial they occurred in 61% and were severe in 4.7%[1]. Most liver enzyme rises came in the first 3 months[1]. Liver tests are checked every 2 weeks for the first 3 months, then once a month and as needed[1].

Lungs: Lung inflammation (interstitial lung disease or pneumonitis) occurred in 1.3%. Alecensa is stopped for good if no other cause is found[1].

Kidneys: Kidney problems occurred in 12%, were severe in 1.7% and were fatal in 0.4%[1].

Heart rate: A slow heart rate occurred in 11%, and 20% of the people with repeated heart tracings had a heart rate under 50 beats a minute after a dose[1]. Heart rate and blood pressure are checked regularly[1].

Muscles: Muscle pain occurred in 31%, and the muscle enzyme CPK rose in 56% of people with lab results, severe in 6%[1]. CPK is checked every 2 weeks for the first month and when someone reports unexplained muscle pain, tenderness or weakness[1].

Red blood cells: Hemolytic anemia, where red blood cells break apart, was first seen after approval and occurred in 3.1% in ALINA[1].

Triglycerides and pancreas: Very high triglycerides, including cases with life-threatening pancreatitis, have been reported since approval[1]. Triglycerides rose in 57% of 98 people tested in 1 trial, severe in 7%, and the label calls for checks before starting and from time to time during treatment[1].

Sun: Sensitivity to sunlight occurred in 9.9% of people in the 2 trials after crizotinib[1]. The label advises avoiding long sun exposure during treatment and for at least 7 days after stopping, and using broad-spectrum sunscreen and lip balm of SPF 50 or higher[1].

Pregnancy: Alecensa can harm an unborn baby[1]. The label calls for effective birth control for women who could become pregnant during treatment and for 5 weeks after the last dose. For men with partners who could become pregnant, it calls for birth control during treatment and for 3 months after[1]. The label also advises against breastfeeding during treatment and for 1 week after the last dose[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Alectinib

The label dose is 600mg by mouth twice a day with food, taken as 4 capsules of 150mg[1]. After surgery, Alecensa is taken for a total of 2 years unless the cancer comes back or side effects become too hard to manage[1]. For metastatic cancer, it is taken until the cancer grows or side effects become too hard to manage[1]. Capsules are swallowed whole and are not opened or dissolved[1]. After a missed dose or vomiting, the next dose is taken at its usual time[1].

For side effects, the doctor may pause Alecensa or lower the dose to 450mg and then 300mg twice a day. Alecensa is stopped in people who cannot tolerate 300mg twice a day[1]. The label dose for severe liver impairment is 450mg twice a day[1].

Before starting: Triglycerides are checked, and a pregnancy test is done for anyone who could become pregnant[1].

During treatment: From the start, liver tests are checked every 2 weeks for the first 3 months and then once a month. CPK is checked every 2 weeks for the first month[1]. Heart rate and blood pressure are checked regularly, and triglycerides from time to time[1].

Testing: For metastatic cancer the ALK test can use tumor tissue or a blood sample. If a blood test finds no ALK change, the label says to test tumor tissue if possible[1]. For use after surgery, the test uses tumor tissue[1].

Other medicines: Studies tested a strong CYP3A inhibitor (posaconazole), a strong CYP3A inducer (rifampin) and a stomach acid reducer (esomeprazole). None of them changed alectinib levels enough to matter, and the label has no medicine interaction section[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Alecensa

With private insurance, the drugmaker's copay card can lower what you pay for Alecensa. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Alecensa (Alectinib)
  • Copay help

    Genentech Oncology Co-pay Assistance Program: eligible commercially insured patients prescribed Alecensa for an FDA-approved use can receive up to $25,000 in assistance per product per calendar year. Not valid when the prescription is reimbursed under any federal or state government program. Call (855) MY-COPAY (855-692-6729), 9 a.m. to 8 p.m. ET, Monday through Friday.

    For: private insurance · source
  • Free medicine program

    Genentech Patient Foundation: people without health insurance coverage, or with financial concerns, who meet eligibility criteria may get Alecensa at no cost. Insured patients with coverage for the medicine should first pursue other forms of financial help if available, and both groups must meet income requirements. Call (888) 941-3331.

    For: no insurance, underinsured · source
  • Insurance and case manager help

    Alecensa Access Solutions can check insurance coverage and prior authorization needs, help with appeals resources, and refer eligible patients with commercial or public insurance to independent co-pay foundations that support lung cancer. Genentech Access Solutions can be reached at (877) GENENTECH / (877) 436-3683.

    For: private insurance, Medicare, Medicaid · source

Good to know: Read on November 18, 2026 from the Genentech Pro Alecensa financial assistance section, the Genentech Oncology Co-pay Assistance Program site (copayassistancenow.com, which only renders in a browser) and Genentech's patient support services page. The old genentech-access.com Alecensa patient links now redirect to gene.com/patients/patient-support-services. Genentech does not publish the Patient Foundation income limits on these pages. The foundations Genentech lists for lung cancer are CancerCare Co-Payment Assistance Foundation, Good Days from CDF, Musella Foundation, Patient Access Network Foundation, Patient Advocate Foundation, The Assistance Fund and HealthWell; their fund status was not checked here.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for ALK-Positive Lung Cancer

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for ALK-Positive Lung Cancer →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

ALINA (NCT03456076) was a randomized, open-label Phase 3 trial in 257 adults whose ALK-positive lung cancer had been fully removed by surgery. The trial included stage IB tumors 4cm or larger through stage IIIA[1][9]. People took alectinib 600mg twice a day for 2 years or 4 cycles of platinum chemotherapy through a vein[1].

Main result: The main measure was disease-free survival. It counted the cancer coming back, a new lung cancer, or death[1]. At the main analysis, one of these happened in 15 of 130 people on alectinib (12%) and 50 of 127 on chemotherapy (39%), a hazard ratio of 0.24[1]. Results were similar in the stage II to IIIA group, and overall survival results were not yet mature[1]. Cancer came back in the brain in 3.1% on alectinib and 11% on chemotherapy, in an exploratory analysis[1].

ALEX (NCT02075840) was a randomized, open-label Phase 3 trial in 303 adults with advanced ALK-positive lung cancer who had not been treated for advanced disease. It compared alectinib 600mg twice a day with crizotinib 250mg twice a day[1][8]. In ALEX, 40% had brain metastases at the start[1].

Main result: Median progression-free survival (the time until the cancer grew) was 25.7 months on alectinib and 10.4 months on crizotinib. These figures were by independent review, with a hazard ratio of 0.53[1]. Tumors shrank in 79% on alectinib and 72% on crizotinib, a difference that was not statistically significant[1]. At the final analysis, overall survival was not formally tested, and the hazard ratio was 0.78[1].

Brain: The brain was the first place the cancer grew in 12% on alectinib and 45% on crizotinib[1]. In 43 people with measurable brain metastases, brain tumors shrank in 81% of 21 on alectinib and 50% of 22 on crizotinib[1].

After crizotinib: The 2015 approval rested on 2 single-arm trials, NP28761 and NP28673, in people whose cancer had grown on crizotinib[1]. Independent reviewers found that tumors shrank in 38% of 87 people and 44% of 138 people, and brain tumors shrank in 61% of 51 people with measurable brain metastases[1].

Development history

Genentech said on December 11, 2015 that the FDA had granted Alecensa accelerated approval for metastatic ALK-positive lung cancer. The approval covered cancer that had grown on crizotinib, or people who could not tolerate crizotinib[2]. On November 6, 2017 the FDA removed the crizotinib requirement based on ALEX, approving Alecensa as a first treatment for metastatic ALK-positive lung cancer[3].

Genentech said the earlier accelerated approval became a full approval[4]. ALINA began in August 2018[9]. Based on ALINA, the FDA approved Alecensa on April 18, 2024 as adjuvant treatment after surgery. This use covers ALK-positive lung cancer with tumors 4cm or larger or cancer in the lymph nodes[5][6]. Genentech called it the first and only ALK inhibitor approved after surgery for early-stage ALK-positive lung cancer[6].

In June 2026 the FDA approved a label update with final ALEX overall survival data[7]. The label also lists an August 2026 change to its warning about very high triglycerides and pancreatitis[1].

Ask anything about Alectinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore ALK-Positive Lung Cancer trials

Other ALK-Positive Lung Cancer treatments

Common questions about Alectinib

▸What is Alectinib (Alecensa)?

Alecensa (alectinib) is a capsule taken twice a day with food for adults with ALK-positive non-small cell lung cancer found by an FDA-approved test[1]. The label covers 2 uses[1]. The first is metastatic disease, meaning cancer that has spread, where Alecensa is taken until the cancer grows or side effects become too hard to manage[1]. The second is adjuvant treatment after surgery has removed the tumor, for tumors 4cm or larger or cancer found in the lymph nodes. In this use, Alecensa is taken for a total of 2 years unless the cancer comes back or side effects become too hard to manage[1]. The FDA first granted accelerated approval on December 11, 2015[2]. It approved Alecensa as a first treatment for metastatic disease on November 6, 2017[3]. The FDA then approved the after-surgery use on April 18, 2024[5]. In the ALINA trial after surgery, the main analysis counted people whose cancer came back, who had a new lung cancer or who died. This happened in 12% of the alectinib group and 39% of the chemotherapy group[1].

▸How does Alectinib work?

In ALK-positive lung cancer, a piece of the ALK gene joins another gene inside the tumor, most often one called EML4. LUNGevity explains that the fused gene makes an abnormal ALK protein that keeps telling cancer cells to grow[12]. LUNGevity also notes that this change is acquired during life rather than inherited from a parent[12]. Alectinib is a kinase inhibitor, a pill that blocks the ALK protein's growth signal and the signals it passes on inside the cell[1]. The body turns alectinib into a breakdown product called M4 that works about as strongly as alectinib itself[1]. In laboratory tests, alectinib and M4 blocked several changed forms of ALK found in tumors that had grown on crizotinib[1]. Alectinib also lengthened survival in mice with ALK-driven tumors placed in the brain[1]. Besides ALK, alectinib blocks a related protein called RET[1].

▸What are the side effects of Alectinib?

Alecensa has no boxed warning and no contraindications[1]. The label's 8 warnings start with liver injury, lung inflammation, kidney problems and a slow heart rate. They also include severe muscle pain with a rise in the muscle enzyme CPK, and a type of anemia in which red blood cells break apart. The other warnings are very high triglycerides that can lead to pancreatitis, and harm to an unborn baby[1].

Most common: The label combines results from 533 people in 4 trials. The most common side effects were liver test changes or liver injury (41%), constipation (39%), tiredness (36%) and muscle pain (31%). Swelling (29%), rash (23%) and cough (21%) were also common[1].

Liver: Liver side effects were severe in 8% of the 533 people, and in the after-surgery ALINA trial they occurred in 61% and were severe in 4.7%[1]. Most liver enzyme rises came in the first 3 months[1]. Liver tests are checked every 2 weeks for the first 3 months, then once a month and as needed[1].

Lungs: Lung inflammation (interstitial lung disease or pneumonitis) occurred in 1.3%. Alecensa is stopped for good if no other cause is found[1].

Kidneys: Kidney problems occurred in 12%, were severe in 1.7% and were fatal in 0.4%[1].

Heart rate: A slow heart rate occurred in 11%, and 20% of the people with repeated heart tracings had a heart rate under 50 beats a minute after a dose[1]. Heart rate and blood pressure are checked regularly[1].

Muscles: Muscle pain occurred in 31%, and the muscle enzyme CPK rose in 56% of people with lab results, severe in 6%[1]. CPK is checked every 2 weeks for the first month and when someone reports unexplained muscle pain, tenderness or weakness[1].

Red blood cells: Hemolytic anemia, where red blood cells break apart, was first seen after approval and occurred in 3.1% in ALINA[1].

Triglycerides and pancreas: Very high triglycerides, including cases with life-threatening pancreatitis, have been reported since approval[1]. Triglycerides rose in 57% of 98 people tested in 1 trial, severe in 7%, and the label calls for checks before starting and from time to time during treatment[1].

Sun: Sensitivity to sunlight occurred in 9.9% of people in the 2 trials after crizotinib[1]. The label advises avoiding long sun exposure during treatment and for at least 7 days after stopping, and using broad-spectrum sunscreen and lip balm of SPF 50 or higher[1].

Pregnancy: Alecensa can harm an unborn baby[1]. The label calls for effective birth control for women who could become pregnant during treatment and for 5 weeks after the last dose. For men with partners who could become pregnant, it calls for birth control during treatment and for 3 months after[1]. The label also advises against breastfeeding during treatment and for 1 week after the last dose[1].

▸How is Alectinib taken?

The label dose is 600mg by mouth twice a day with food, taken as 4 capsules of 150mg[1]. After surgery, Alecensa is taken for a total of 2 years unless the cancer comes back or side effects become too hard to manage[1]. For metastatic cancer, it is taken until the cancer grows or side effects become too hard to manage[1]. Capsules are swallowed whole and are not opened or dissolved[1]. After a missed dose or vomiting, the next dose is taken at its usual time[1].

For side effects, the doctor may pause Alecensa or lower the dose to 450mg and then 300mg twice a day. Alecensa is stopped in people who cannot tolerate 300mg twice a day[1]. The label dose for severe liver impairment is 450mg twice a day[1].

Before starting: Triglycerides are checked, and a pregnancy test is done for anyone who could become pregnant[1].

During treatment: From the start, liver tests are checked every 2 weeks for the first 3 months and then once a month. CPK is checked every 2 weeks for the first month[1]. Heart rate and blood pressure are checked regularly, and triglycerides from time to time[1].

Testing: For metastatic cancer the ALK test can use tumor tissue or a blood sample. If a blood test finds no ALK change, the label says to test tumor tissue if possible[1]. For use after surgery, the test uses tumor tissue[1].

Other medicines: Studies tested a strong CYP3A inhibitor (posaconazole), a strong CYP3A inducer (rifampin) and a stomach acid reducer (esomeprazole). None of them changed alectinib levels enough to matter, and the label has no medicine interaction section[1].

▸Is Alectinib FDA approved?

Yes, Alectinib (Alecensa) is FDA approved (2015) for the treatment of ALK-Positive Lung Cancer.

▸How long can you take alectinib?

The length depends on the use, a total of 2 years after surgery, or no set end date for cancer that has spread.

After surgery: The label gives Alecensa for a total of 2 years, or until the cancer comes back or side effects become too hard to manage.

Metastatic cancer: The label gives Alecensa until the cancer grows or side effects become too hard to manage.

In ALEX: Median time before the cancer grew was 25.7 months on alectinib and 10.4 months on crizotinib.

More: ALK-positive lung cancer treatments compared

Source: Alecensa prescribing information, DailyMed

▸What are the side effects of Alecensa?

Across 533 people in 4 trials, the most common side effects were liver test changes or liver injury (41%), constipation (39%) and tiredness (36%). Muscle pain (31%), swelling (29%), rash (23%) and cough (21%) were also common.

Warnings: Liver injury, lung inflammation, kidney problems, a slow heart rate and severe muscle pain with a rise in CPK. The label also warns of hemolytic anemia, very high triglycerides that can lead to pancreatitis, and harm to an unborn baby.

Monitoring: Liver tests are done every 2 weeks for the first 3 months, and CPK every 2 weeks for the first month. Heart rate, blood pressure and triglycerides are checked regularly.

Sun: Sensitivity to sunlight occurred in 9.9% in 2 trials.

Boxed warning: None.

Source: Alecensa prescribing information, DailyMed

▸Is alectinib a chemo?

No. Alectinib (Alecensa) is a targeted pill called a kinase inhibitor, not chemotherapy.

How it works: Alectinib blocks the abnormal ALK protein that drives ALK-positive lung cancer.

After surgery: In the ALINA trial, alectinib for 2 years was compared with 4 cycles of platinum chemotherapy. At the main analysis, the cancer came back, a new lung cancer appeared or the person died in 12% on alectinib and 39% on chemotherapy.

How it's taken: The dose is 600mg by mouth twice a day with food.

Source: Alecensa prescribing information, DailyMed

▸Does alectinib make you sensitive to the sun?

Yes, the Alecensa label lists sensitivity to sunlight as a side effect.

How often: Sun sensitivity occurred in 9.9% of people in the 2 trials after crizotinib, in 5.3% in ALEX and in 3.9% in ALINA. Nearly all cases in the first 2 trials were mild.

Label advice: The label advises avoiding long sun exposure during treatment and for at least 7 days after stopping. It also advises using broad-spectrum UVA and UVB sunscreen and lip balm of SPF 50 or higher.

Source: Alecensa prescribing information, DailyMed

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
  2. Genentech, Inc. · 2015-12-11. FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer. https://www.gene.com/media/press-releases/14615/2015-12-11/fda-grants-genentechs-alecensa-alectinib
  3. U.S. Food and Drug Administration · 2017-11-06. NDA 208434/S-03 SUPPLEMENT APPROVAL FULFILLMENT OF POSTMARKETING REQUIREMENT. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208434Orig1s003ltr.pdf
  4. Genentech, Inc.. FDA Approves Genentech Medicine for First-Line Treatment of Specific Type of Lung Cancer. https://www.gene.com/media/news-features/fda-approves-genentech-medicine-for-first-line-treatment-of-specific-type-of-lung-cancer
  5. U.S. Food and Drug Administration · 2024-04-18. NDA 208434/S-015 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208434Orig1s015ltr.pdf
  6. Genentech, Inc. · 2024-04-18. FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer. https://www.gene.com/media/press-releases/15023/2024-04-18/fda-approves-genentechs-alecensa-as-firs
  7. U.S. Food and Drug Administration · 2026-06-11. NDA 208434/S-016 SUPPLEMENT APPROVAL/ FULFILLMENT OF POSTMARKETING COMMITMENT. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/208434Orig1s016ltr.pdf
  8. ClinicalTrials.gov · 2026-11-18. A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants. https://clinicaltrials.gov/study/NCT02075840
  9. ClinicalTrials.gov · 2026-11-18. A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03456076
  10. ClinicalTrials.gov · 2026-11-18. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer. https://clinicaltrials.gov/study/NCT03596866
  11. ClinicalTrials.gov · 2026-11-18. Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC. https://clinicaltrials.gov/study/NCT06765109
  12. LUNGevity Foundation. About ALK-positive Lung Cancer | Navigating ALK. https://alk.lungevity.org/alk/about-alk-positive-lung-cancer
  13. U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
  14. U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
  15. U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
  16. U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e
  17. U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e
  18. Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Alecensa by email

We'll email you when Alecensa's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site